MENLO PARK, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today...

MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from chronic or debilitating disease, today reported financial...

Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT MENLO PARK, Calif. and PARIS, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc....

MENLO PARK, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced...

MENLO PARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported...

MENLO PARK, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported...

World Economic Forum Today Announced Its Selection of the World's 49 Most Promising Technology Pioneers 2015 Avalanche is Recognized for Achievements in Gene Therapy Technology US and UK-based Companies Make up 80% of Awardees The Full List of Recognized Technology...

–Thomas W. Chalberg, Jr., Ph.D. Resigns as CEO and Board Member, Continues as Scientific Advisor – – Hans P. Hull Appointed Interim CEO and President – – Avalanche Co-founder Mitchell H. Finer Takes on New Role as Distinguished Research Fellow– MENLO PARK, Calif.,...

MENLO PARK, CA -- (Marketwired) -- 06/15/15 -- - Phase 2a study met primary endpoint while demonstrating promising treatment effect on visual acuity maintenance with less frequent injections - Phase 1 36-month follow-up data demonstrates continued safety and...

MENLO PARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need,...